Abstract
Background: Healthy microvasculature provides nutrient and oxygen delivery and removes waste
metabolites critical for sustained tissue viability and function after wound healing. Processed
microvascular tissue (PMVT), a novel allograft, aims to directly address the compromised
microvasculature found in chronic and complex wounds.
Aim: Building on a Level 1 randomized controlled trial demonstrating improved healing and
lower extremity sensation with PMVT in neuropathic diabetic foot ulcers, along with a sub-study
demonstrating increased wound area blood flow, this article details the authors’ clinical experience
with PMVT in a case series of challenging wounds, including diabetic foot ulcer, Charcot foot
ulcer, venous leg ulcer, and Mohs surgical wound cases.
Methods: Patients received weekly or semi-weekly topical PMVT treatment until wound
sites demonstrated active healing with evidence of good microcirculation and progressing reepithelialization.
In all cases, PMVT was covered with a non-adherent dressing and left untouched
between visits. Patients were directed not to change the wound dressing, to comply with standard
care guidance appropriate for each of their wounds, and to return weekly for assessment of the
wound and (if needed) reapplication of the PMVT product. Wound size was measured using a ruler
at each visit.
Results: Closure criteria were 100% epithelialization with no maceration, exudate, or signs of
infection. The topical application of PMVT successfully healed all challenging or at-risk wounds
evaluated in this clinical case series.
Conclusion: By repairing the deficient local microvasculature within and around the wounds,
PMVT was able to facilitate the delivery of oxygen and nutrients to the ulcer and enable healing.
Relevance for Patients: PMVT demonstrates the potential to be a strong advanced wound care
technology for the treatment of chronic and complex wounds that are refractory to standard care.
DOI: http://doi.org/10.36922/jctr.24.00059
Author affiliation
1The Healing Center at Mercy Medical Center, Cedar Rapids, Iowa, United States of America
2MicroVascular Tissues, Inc., San Diego,
California, United States of America
*Corresponding author:
Jonathan F. Arnold, M.D.
Medical Director, The Healing Center,
Mercy Medical Center, Cedar Rapids, Iowa,
United States of America
Email: jarnold@mercycare.org
Downloads:
Full-text PDF
